Konstantinidis Lazaros, Roberts Dawn, Errington R Douglas, Kacperek Andrzej, Heimann Heinrich, Damato Bertil
Vitreoretinal and Ocular Oncology Service, Royal Liverpool University Hospital, Liverpool, UK.
Liverpool Ocular Oncology Research Group, Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, UK.
Br J Ophthalmol. 2015 Feb;99(2):232-5. doi: 10.1136/bjophthalmol-2014-305313. Epub 2014 Aug 19.
Collateral damage to upper eyelid margin during proton beam radiotherapy (PBR) for choroidal melanoma may cause squamous metaplasia of the tarsal conjunctiva with keratinisation, corneal irritation, discomfort and, rarely, corneal perforation. We evaluated transpalpebral PBR as a means of avoiding collateral damage to the upper eyelid margin without increasing the risk of failure of local tumour control.
Retrospective study of consecutive patients who underwent PBR for choroidal melanoma between 1992 and 2007 at the Royal Liverpool University Hospital and the Douglas Cyclotron at Clatterbridge Cancer Centre, UK.
Sixty-three patients were included in this study. Mean basal tumour diameter and tumour thickness were 11.8 mm and 3.6 mm, respectively. PBR mean beam range and modulation were 26.5 mm and 16.9 mm respectively. The eyelid margin was included in the radiation field in 15 (24%) eyes. The median follow-up was 2.5 years. Local tumour recurrence developed in 2 (3.2%) patients. In these two cases that developed tumour recurrence the transpalpebral treatment did not involve the eyelid margin. Six (9.5%) patients died of metastatic disease. No eyelid or ocular surface problems developed in any of the 48 patients who were treated without eyelid rim involvement, while 7 of the 15 patients with unavoidable irradiation of the eyelid rim developed some degree of madarosis. These seven patients all received more than 26.55 proton Gy to the eyelid margin. Symptoms, such as grittiness occurred in 12% of 48 patients without eyelid margin irradiation as compared with 53% of 15 patients whose lid margin was irradiated.
Transpalpebral PBR of choroidal melanoma avoids eyelid and ocular surface complications without increasing failure of local tumour control.
脉络膜黑色素瘤质子束放疗(PBR)期间对上睑缘的附带损伤可能导致睑板结膜鳞状化生伴角化、角膜刺激、不适,且极少情况下会导致角膜穿孔。我们评估了经睑质子束放疗作为一种避免对上睑缘造成附带损伤且不增加局部肿瘤控制失败风险的方法。
对1992年至2007年期间在英国皇家利物浦大学医院和克莱特布里奇癌症中心道格拉斯回旋加速器接受脉络膜黑色素瘤质子束放疗的连续患者进行回顾性研究。
本研究纳入63例患者。肿瘤基底平均直径和厚度分别为11.8毫米和3.6毫米。质子束放疗的平均射野范围和调制度分别为26.5毫米和16.9毫米。15只眼(24%)的睑缘被纳入辐射野。中位随访时间为2.5年。2例(3.2%)患者出现局部肿瘤复发。在这两例发生肿瘤复发的病例中,经睑治疗未累及睑缘。6例(9.5%)患者死于转移性疾病。在48例未累及睑缘的患者中,无一例出现眼睑或眼表问题,而在15例不可避免累及睑缘的患者中,7例出现了一定程度的睫毛脱落。这7例患者的睑缘均接受了超过26.55质子戈瑞的照射。48例未接受睑缘照射的患者中,12%出现如眼内有沙粒感等症状,而15例接受睑缘照射的患者中,53%出现了此类症状。
脉络膜黑色素瘤经睑质子束放疗可避免眼睑和眼表并发症,且不增加局部肿瘤控制失败的风险。